Alantolactone ameliorates graft versus host disease in mice
Yazarlar (17)
Gül Pelin Odabaş
Türkiye
Türkiye
Kübra Aslan Türkiye
Pınar Alisan Suna
Perihan Kader Kendirli
Dr. Öğr. Üyesi Şerife ERDEM Türkiye
Mustafa Çakır Türkiye
Alper Özcan Türkiye
Ebru Yılmaz Türkiye
Musa Karakükcü Türkiye
Hamiyet Altuntaş Türkiye
Arzu Hanım Yay Türkiye
Kemal Deniz Türkiye
Derya Altay Türkiye
Duran Arslan Türkiye
Halit Canatan Türkiye
Ahmet Eken Türkiye
Ekrem Ünal Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | International Immunopharmacology (Q1) | ||
| Dergi ISSN | 1567-5769 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 02-2024 |
| Cilt / Sayı / Sayfa | 128 / 0 / – | DOI | 10.1016/j.intimp.2024.111560 |
| Makale Linki | http://dx.doi.org/10.1016/j.intimp.2024.111560 | ||
| Özet |
| The anti-inflammatory and immunosuppressive drugs which are used in the treatment of Graft-versus-Host Disease (GVHD) have limited effects in controlling the severity of the disease. In this study, we aimed to investigate the prophylactic effect of Alantolactone (ALT) in a murine model of experimental GVHD. The study included 4 BALB/c groups as hosts: Naïve (n = 7), Control GVHD (n = 16), ALT-GVHD (n = 16), and Syngeneic transplantation (n = 10). Busulfan (20 mg/kg/day) for 4 days followed by cyclophosphamide (100 mg/kg/day) were administered for conditioning. Allogeneic transplantation was performed with cells collected from mismatched female C57BL/6, and GVHD development was monitored by histological and flow cytometric assays. Additionally, liver biopsies were taken from GVHD patient volunteers between ages 2-18 (n = 4) and non-GVHD patients between ages 2-50 (n = 5) and cultured ex vivo with ALT, and the supernatants were used for ELISA. ALT significantly ameliorated histopathological scores of the GVHD and improved GVHD clinical scores. CD8 T cells were shown to be reduced after ALT treatment. More importantly, ALT treatment skewed T cells to a more naïve phenotype (CD62L CD44). ALT did not alter Treg cell number or frequency. ALT treatment appears to suppress myeloid cell lineage (CD11c). Consistent with reduced myeloid lineage, liver and small intestine levels of GM-CSF were reduced in ALT-treated mice. IL-6 gene expression was significantly reduced in the intestinal tissue. Ex vivo ALT-treated liver biopsy samples from GVHD patients showed a trend of decrease in pro-inflammatory cytokines but there was no statistical significance. Collectively, the data indicated that ALT may have immunomodulatory actions in a preclinical murine GVHD model. |
| Anahtar Kelimeler |
| Alantolactone | Graft versus host disease | Bone marrow transplantation | Allogenic transplantation | Autoimmunity |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Web of Science | 3 |